MCK
McKesson Corporation · Healthcare · Medical - Distribution
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 4 | 0 | 491.74K | $432.26M | n/a | −2 |
| Q2 2026 | 170 | 0 | 84.19M | $63.78B | +6 | −7 |
| Q1 2026 | 174 | 0 | 86.49M | $74.72B | +5 | −6 |
| Q4 2025 | 173 | +2 | 91.21M | $74.82B | +3 | n/a |
| Q3 2025 | 22 | 0 | 48.07M | $37.12B | +1 | −2 |
| Q2 2025 | 20 | -1 | 40.25M | $29.48B | n/a | −1 |
| Q1 2025 | 18 | -1 | 15.05M | $10.13B | +1 | −2 |
| Q4 2024 | 19 | +1 | 15.70M | $8.94B | +1 | n/a |
| Q3 2024 | 17 | -1 | 9.08M | $4.48B | +1 | −2 |
| Q2 2024 | 18 | n/a | 11.69M | $6.82B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Assenagon Asset Management S.A. | 243.10K | +121.4% | $207.56M | 0.2% | ▲ Add | 4 | SEC ↗ |
| 2 | Wealth Enhancement Advisory… | 109.80K | +2.0% | $101.47M | 0.2% | ▲ Add | 4 | SEC ↗ |
| 3 | TD Waterhouse Canada Inc. | 100.12K | +2.8% | $90.17M | 0.2% | ▲ Add | 4 | SEC ↗ |
| 4 | Ninety One UK Ltd | 38.72K | -13.9% | $33.06M | 0.1% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Robeco Institutional Asset… | $177.38M | was 0.2% |
| Assetmark, Inc | $30.44M | was 0.1% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 2,017 holders, 102.83M shares, $85.35B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 800 sh · $797,129
Officer · 111 sh · $98,951
Director · 301 sh · $268,590
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology